Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129984 | 1.00 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL628900 | 1.00 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13669545 | 0.91 | CTSK (0.54) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8089276 | 0.90 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL2770105 | 0.90 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL2074989 | 0.90 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL24177101 | 0.88 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL9191203 | 0.88 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21660257 | 0.88 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20936155 | 0.87 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| CN-1898227-A | As prostaglandin E2Ornithine derivatives as agonists or antagonists | ASTELLAS PHARMA INC (JP) | 2007-01-17 | — | — | CN | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-0812835-B1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5925658-A | PREVENTING OR TREATING ANGINA PECTORIS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| US-5891898-A | ANTIULCER AGENT | SANKYO COMPANY, LIMITED (JP) | 1999-04-06 | — | — | US | disclosed |
| EP-0812835-A1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | BACE1, PSEN1, BACE2 | CTSK 238/4885CTSS 57/4885CA1 895/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CTSK 820/4885CTSS 898/4885CA1 1969/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | CTSK 2499/4885CTSS 624/4885CA1 1017/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CTSK 243/4885CTSS 112/4885CA1 3625/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | CTSK 2765/4885CTSS 807/4885CA1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.